Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
4.220
-0.090 (-2.09%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Cytek Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 204.17 | 201.49 | 200.45 | 193.02 | 164.04 | 127.95 | |
Revenue Growth | 3.61% | 0.52% | 3.85% | 17.67% | 28.20% | 37.82% |
Cost of Revenue | 98.61 | 97.03 | 89.35 | 83.59 | 63.06 | 48.81 |
Gross Profit | 105.56 | 104.46 | 111.11 | 109.43 | 100.97 | 79.14 |
Selling, General & Admin | 113.08 | 108.38 | 92.23 | 93.12 | 67.92 | 45.55 |
Research & Development | 36.35 | 36.47 | 39.4 | 44.15 | 34.86 | 24.44 |
Total Operating Expenses | 149.43 | 144.84 | 131.63 | 137.27 | 102.78 | 69.99 |
Operating Income | -43.87 | -40.38 | -20.52 | -27.85 | -1.8 | 9.16 |
Interest Income | 2.5 | 2.22 | 5.12 | 6.41 | 4.62 | 0.05 |
Interest Expense | -1.17 | - | - | - | - | -1.74 |
Other Non-Operating Income (Expense) | 5.88 | 8.33 | 9.7 | 5.72 | -1.56 | -1.53 |
Total Non-Operating Income (Expense) | 7.2 | 10.54 | 14.82 | 12.14 | 3.06 | -3.22 |
Pretax Income | -36.67 | -29.84 | -5.7 | -15.71 | 1.26 | 5.94 |
Provision for Income Taxes | -1.19 | 36.7 | 0.32 | -3.56 | -1.22 | 2.91 |
Net Income | -35.48 | -66.54 | -6.02 | -12.15 | 2.48 | 3.03 |
Minority Interest in Earnings | - | - | - | - | 0.09 | -3.03 |
Net Income to Common | -35.48 | -66.54 | -6.02 | -12.15 | 2.58 | 6.05 |
Net Income Growth | - | - | - | - | -57.45% | 88.25% |
Shares Outstanding (Basic) | 128 | 128 | 131 | 135 | 135 | 77 |
Shares Outstanding (Diluted) | 128 | 128 | 131 | 135 | 139 | 82 |
Shares Change | -2.31% | -2.19% | -3.45% | -2.37% | 69.93% | 150.13% |
EPS (Basic) | -0.57 | -0.52 | -0.05 | -0.09 | 0.02 | - |
EPS (Diluted) | -0.57 | -0.52 | -0.05 | -0.09 | 0.02 | - |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -9.3 | -8.77 | 21.85 | 0.63 | -21.98 | 0.27 |
Free Cash Flow Growth | - | - | 3352.45% | - | - | -98.05% |
Free Cash Flow Per Share | -0.07 | -0.07 | 0.17 | 0.00 | -0.16 | 0.00 |
Gross Margin | 51.70% | 51.84% | 55.43% | 56.69% | 61.56% | 61.86% |
Operating Margin | -21.49% | -20.04% | -10.24% | -14.43% | -1.10% | 7.16% |
Profit Margin | -17.38% | -33.02% | -3.00% | -6.29% | 1.51% | 2.37% |
FCF Margin | -4.56% | -4.35% | 10.90% | 0.33% | -13.40% | 0.21% |
EBITDA | -31.97 | -28.41 | -10.03 | -18.62 | 3.86 | 10.4 |
EBITDA Margin | -15.66% | -14.10% | -5.01% | -9.64% | 2.35% | 8.13% |
EBIT | -43.87 | -40.38 | -20.52 | -27.85 | -1.8 | 9.16 |
EBIT Margin | -21.49% | -20.04% | -10.24% | -14.43% | -1.10% | 7.16% |
Effective Tax Rate | 3.25% | -122.98% | -5.61% | 22.67% | -97.14% | 49.02% |